News
We send the latest information from SMC Laboratories.
Our clients’ presentations at AASLD ~The Liver Meeting 2024 ~
Our clients presented data on treatment of MASH using STAMTM model at the AASLD ~The Liver Metting 2024~ (November 15-19). For detailed information, see the below URL. aasld.org/sites/default/files/2024-10/1_the_liver_meeting_2024_abstracts.pdf Poster #1060 The beneficial effect of resmetirom on tumorigenesis associated with MASH in STAM mice Institution: Kurume University School of Medicine (Japan) Poster #1082 Impact…
MOA demonstration #4 【Gut-Liver Axis】｜Evaluation of the efficacy of a compound in the treatment of MASH via the Gut-Liver Axis using STAM™ mice
Today, we introduce the pre-clinical studies in MASH drug development targeting Gut-Liver axis. In MASH patients, changes in the microbiome and increased intestinal permeability (Leaky Gut) have been observed (Lixin et al., Hepatology, 2012; Jay et al., CMGH, 2015). In fact, analyses in mouse models have shown that dysfunction of the gut-liver axis, such…
Case study: Study published in Biomolecules on the effects of MSC-sEV in skin fibrosis of BLM-SSc model.
We introduce a case study of drug efficacy evaluation of Mesenchymal stem/stromal cell-derived small extracellular vesicles (MSC-sEVs) using our Systemic sclerosis (SSc) model, BLM-SSc model. Title: An Assessment of Administration Route on MSC-sEV Therapeutic Efficacy ( Zhang B et al., Biomolecules. 2024 ) Article Link ► [DOI: 10.3390/biom14060622] In this study, we administered intraperitoneally, subcutaneously,…
The STAM™ mouse: a clinically relevant, spontaneous HCC model
We would like to introduce a study published by our client using our STAM™ mouse (Dow, et al. Proc Natl Acad Sci U S A. 2018). Title: Integrative genomic analysis of mouse and human hepatocellular carcinoma Dow, et al. Proc Natl Acad Sci U S A. 2018 The STAM™ model is a…
MOA demonstration #3 【GLP-1】｜Evaluation of GLP-1 targeted MASH treatment efficacy using STAM™ mice
Today, we introduce the pre-clinical studies in MASH drug development targeting GLP-1. Speaking of GLP-1, Wegovy® (semaglutide), approved by the FDA for the treatment of obesity, is a GLP-1 receptor agonist. GLP-1 receptor agonists such as semaglutide were initially developed for the treatment of diabetes, but drug discovery research has been conducted to expand…
MOA demonstration #2【diponectin】｜A drug efficacy evaluation study using STAM™ mice “Inhibition of MASH and fibrosis progression by adiponectin-derived peptide”.
We introduce the pre-clinical studies in MASH drug development using Adiponectin, adipoR1 , adipoR2, etc. as MOA. Demonstration of adiponectin-derived peptide ALY688 in a drug evaluation study using STAM™ mice ►The adiponectin‐derived peptide ALY688 protects against the development of metabolic dysfunction‐associated steatohepatitis – Huang – 2024 – Clinical and Translational Science – Wiley Online…
Drug efficacy evaluation study for fibrotic diseases involving multiple organs
If the therapeutic drug you are developing targets a factor that is related to a multi-organ pathology, such as inflammation or fibrosis, our services for drug evaluation studies can help to bring out the maximal efficacy. Today, we want to introduce a paper by Insilico Medicine, a company that focuses on fibrosis to develop…
Poster presentation selected for the EASL Congress 2024, data on STAM mice in the field of Immune-oncology
We are pleased to announce that the latest pathology and pathogenesis data in the field of immuno-oncology on STAM™-HCC/IO⁺ mouse will be presented in a poster at the EASL Congress 2024 in Milan, Italy, June 5-8, 2024. The STAM™-HCC/IO⁺ mouse is the first preclinical model in the field of immuno-oncology for the development of new…
Study published in Sci Transl Med. on the effects of A monoclonal antibody targeting nonjunctional claudin-1 in CKD of UUO model.
We introduce a case study of drug efficacy evaluation of anti-claudin-1 antibody using our chronic kidney disease model, UUO model. Title: A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity ( Roehlen et al., Sci Transl Med. 2022 ) Article Link ► [DOI: 10.1126/scitranslmed.abj4221] In this study, we administered…
Study published in Cells. on the effects of ameliorating epigenetic modifications by ATP1A1 signalosome inhibition in the liver cancer of STAM™ mice
SMC is proud to announce that Marshall University (WV) has published the results of their study using our pre-clinical services with the STAM™ mice in Cells. Title: Normalization of the ATP1A1 Signalosome Rescinds Epigenetic Modifications and Induces Cell Autophagy in Hepatocellular Carcinoma (Rajan PK et al., Cells. 2023) Article Link ► [DOI: 10.3390/cells12192367] In this…